Patents Assigned to IDM Pharma, Inc.
  • HLA-A2 Tumor Associated Antigen Peptides and Compositions
    Publication number: 20100209493
    Abstract: A peptide or composition comprising at least one HLA-A2 epi tope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 19, 2010
    Applicant: IDM Pharma, Inc.
    Inventors: John D. FIKES, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA binding peptides and their uses
    Publication number: 20090012004
    Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu.
    Type: Application
    Filed: August 3, 2007
    Publication date: January 8, 2009
    Applicant: IDM Pharma, Inc.
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis
  • HLA binding peptides and their uses
    Patent number: 7252829
    Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: August 7, 2007
    Assignee: IDM Pharma, Inc.
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Esteban Celis